Fri, Mar 6, 2015, 12:18 AM EST - U.S. Markets open in 9 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

tensgut 15 posts  |  Last Activity: Mar 4, 2015 11:24 AM Member since: Oct 14, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Keep your eye on Stryker

    by ozark580 Mar 4, 2015 10:24 AM
    tensgut tensgut Mar 4, 2015 11:24 AM Flag

    Osiris will receive $5 million with the first sale of Bio4. This could happen anyday now. I am looking forward to the Stryker rollout with all of the bells and whistles. Time to let the Stryker sales force loose and sell the heck out of Bio4.

  • Reply to

    New position -OSIR

    by prospern23 Mar 3, 2015 2:19 PM
    tensgut tensgut Mar 4, 2015 7:15 AM Flag

    Congrats on your ANY. Looks like it is coming back!

  • Reply to

    questions for cc

    by ch47ady Feb 15, 2015 2:51 AM
    tensgut tensgut Feb 17, 2015 1:02 PM Flag

    ch47ady, I believe the New Venturetec annual meeting was last week. Did you attend? Did you get any interesting information that you could share with the board?

  • Reply to

    questions for cc

    by ch47ady Feb 15, 2015 2:51 AM
    tensgut tensgut Feb 15, 2015 11:12 AM Flag

    One day, a few of us should get together and go fishing. Let's include Ozark who is also an avid fisherman. Once Osiris hits triple digits, let's plan on that special vacation, anywhere in the world......

  • Reply to

    questions for cc

    by ch47ady Feb 15, 2015 2:51 AM
    tensgut tensgut Feb 15, 2015 10:15 AM Flag

    Is that Roger's house that has been rebuilt next to Peter or has Roger decided not to build?

  • Reply to

    Interesting Theory

    by market_mania Jan 24, 2015 6:33 PM
    tensgut tensgut Jan 25, 2015 9:40 AM Flag

    For now Osiris is a biosurgery company focusing on potential multi-million/billion products that can be used today that do not have to go through the lengthy, extremely costly and unknown FDA process or success. Will Osiris try to make a drug again and actually have a therapeutic side? Osiris has so many angles for new products that they can develop. There currently is a lack of money, scientists and manpower to go all out. If Osiris decides to develop drugs, I could see a split up between the therapeutics and the biosurgery products. Perhaps one of the reasons why Osiris has not changed it's name from Osiris Therapeutics to Osiris Biosurgery is because they may be planning to develop a new and better stem cell drug.

  • Reply to

    Interesting Theory

    by market_mania Jan 24, 2015 6:33 PM
    tensgut tensgut Jan 24, 2015 8:37 PM Flag

    There is no question, Hansjorg could be the wild card. Something is brewing between Peter and Hansjorg. I, for one, would love to see a secondary offering. Osiris could raise $100 or $200 million or possibly more. This money could be used to buy an existing struggling complementary company(s) with important patents, intellectual rights, trade secrets, established management, sales people and ipossibly a state of the art facilty with a likekind biosurgery manufacturing capabilitiy. Monies could also be used for multiple BLA's, hirings, research and promotion, or a second building and biosurgery manufacturing facility.

    Sometime in the near future, the Osiris headquarters in Columbia, MD will no longer be able to manufacture enough of their biosurgery products as demand will exceed their supply. I expect that Osiris may soon have to outsource their biosurgery products to other manufacturers to keep up supply. Arthrex for Cartiform and Stryker for Bio4 seems logical.

  • Reply to

    Minnesota - Osiris Share Breakdown/Analysis

    by market_mania Jan 23, 2015 9:40 PM
    tensgut tensgut Jan 24, 2015 6:10 PM Flag

    Hansjorg was supposedly brought in as a strategic advisor. What does that mean? What is Hansjorg's purpose? At the last annual meeting I asked Lode this question. Peter immediately stopped Lode from attempting to answer this question. Peter strode to the front of the room and merely stated that Hansjorg was his friend. Whatever the answer, I like having as least two billionaires on board.

  • Reply to

    Minnesota - Osiris Share Breakdown/Analysis

    by market_mania Jan 23, 2015 9:40 PM
    tensgut tensgut Jan 24, 2015 10:03 AM Flag

    When do you suppose that the second richest person in Switzerland will buy in?

  • Reply to

    Osiris - there they go again...

    by ozark580 Jan 12, 2015 8:24 AM
    tensgut tensgut Jan 12, 2015 12:13 PM Flag

    MENVIVO trademark by Osiris Therapeutics, Inc. in Columbia, MD, 21046

    medical knee implant for healing and repairing meniscal tears and damage

  • Reply to

    Thinking out loud

    by ozark580 Dec 27, 2014 9:16 AM
    tensgut tensgut Dec 27, 2014 12:47 PM Flag

    Mcbride, for now Osiris has royalty rights. But they still own Cartiform and Bio4. The sales value will be much higher for Bio4 as worldwide sales occur.

  • Reply to

    Thinking out loud

    by ozark580 Dec 27, 2014 9:16 AM
    tensgut tensgut Dec 27, 2014 11:30 AM Flag

    Number One. Osiris is not for sale. Not until the fruit ripens and maybe not even then.

    Number Two. There is more value than just these four biosurgery products. There is the unknown pipeline of other biosurgery products to come, such as the "miniscus" product to be unveiled later this year and upgraded products. And then there are the numerous patents, intellectual rights and trade secrets. And don't forget one of the most important assets, management and staff.

    Number Three. I have waited patiently, I will wait some more. More will happen to this great innovative company.

  • Osiris is entitled to receive an initial exclusivity fee of $5,000,000 and additional fees upon any exercise by Stryker of its right to extend the initial term, whether on an exclusive or non-exclusive basis. These additional fees are reduced on a sliding scale if Stryker meets certain revenue thresholds during the term then ending, or if revenue goals are not met as a result of Osiris not fulfilling its supply obligations.

  • PLAINSBORO, N.J., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (IART) today announced the expansion of its skin and wound product line with the introduction of Integra(R) Meshed Dermal Regeneration Template. Integra Meshed Dermal Regeneration Template has received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA), and expects to begin a full market release in the United States in January 2015. Integra's newest skin product will be featured at the John A. Boswick Burn and Wound Care Symposium, February 14-18, 2015.

    "Integra Meshed Dermal Regeneration Template is currently the only pre-meshed bilayer matrix approved by the FDA for third-degree burns and scar contracture procedures," said William Weber, Vice President and General Manager, Integra Orthopedics and Tissue Technologies. "It complements our burn product portfolio, and combines the proven collagen technology of Integra Dermal Regeneration Template with the convenience of a pre-meshed configuration."

    Integra Meshed Dermal Regeneration Template is a collagen-chondroitin-6-sulfate, pre-meshed bilayer matrix indicated for the postexcisional treatment of life-threatening full-thickness or deep partial-thickness thermal injuries, and the repair of scar contractures when other therapies have failed. Terminally sterilized, Integra Meshed Dermal Regeneration Template is conveniently stored at room temperature, has a 24-month shelf life, and is intended for one-time use.

    Integra offers a versatile range of skin repair solutions to meet the surgeon's procedural needs, including Integra(R) Dermal Regeneration Template, one of the first regenerative medicine products approved by the FDA; Integra(R) Meshed Bilayer Wound Matrix, which can be used with Negative Pressure Wound Therapy; and Integra(R) Flowable Wound Matrix, designed for easy application to tunneled and/or undermined wounds.

  • tensgut tensgut Dec 6, 2014 5:15 PM Flag

    Very interesting. Cryopreservation apparently has some benefits over the dried product as far as viabie cells which could be more beneficial to the patient depending on the severity and size of the nonhealing wound. The dried product, Epifix, certainly has advantages over the cryopreserved product since it does not need to be frozen and thawed, and it is truly off the shelf and can be used immediately. As I have previously stated, I am a shareholder in both MiMedx and Osiris. There is plenty of room for both products. GLTA

OSIR
16.94-0.86(-4.83%)Mar 5 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST